Navigation Links
GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
Date:8/27/2010

these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV immune responses, as well as the vaccines' safety. Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals infected with HIV. Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax. For more information, please visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more e
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
6. GeoVax to Present at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax to Exhibit at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... With the ability to record continuously at over 500 ... minutes, Fastec Imaging has brought the same ease-of-use of today’s ... a high speed camera that can be used as simply ... proclaims Matt Kearney, VP of Sales for Fastec Imaging. ... simplify the traditionally complicated workflow of a high speed camera. ...
(Date:7/23/2014)... Cambridge, MA (PRWEB) July 23, 2014 ... provider of innovative and comprehensive consultancy and pharma ... Research Excellence and Safety (ACRES) , a non-profit ... worldwide to build and maintain a global system ... strategic alliance collaboration to improve the expertise of ...
(Date:7/22/2014)... of Standards and Technology (NIST) and California Institute ... for an atomic clock that is based on ... The microcomb clock, featured on the cover of ... Optica ,* is the first demonstration of all-optical ... of optical frequencies to lower microwave frequencies. (Optical ...
(Date:7/22/2014)... York (PRWEB) July 22, 2014 Nuclear ... The heat produced by controlled fission chain reaction in ... steam pressure is used to drive a power- generating ... 19% of the world’s total electricity production. Nuclear reactor ... several under construction, planned and proposed nuclear reactor projects. ...
Breaking Biology Technology:Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3'Comb on a chip' powers new NIST/Caltech atomic clock design 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... Inc. (NYSE Amex: PIP ), a biodefense ... announced today that results from a second Phase II ... Annual Conference on Vaccine Research, being held in Baltimore, ... the National Foundation of Infectious Diseases.David P. Wright, President ...
... 28 Techne Corporation (Nasdaq: TECH ) announced ... dividend of $0.25 per share for the quarter ended March ... 22, 2009 to all common shareholders of record on May ... the Board of Directors on a quarterly basis.Techne,s Board of ...
... for Mycobacterium tuberculosis (TB) Expected to Highlight Broad On-Demand ... 28 Cepheid (Nasdaq: CPHD ) today ... Patient Management in the Era of Rapid Diagnostics ," ... Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking ...
Cached Biology Technology:PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 2PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 4PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 5PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 6PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 7Techne Corporation Declares Dividend and Announces an Increase in Its Share Repurchase Program 2Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 3Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 4Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 5
(Date:7/23/2014)... As of 2015, Springer will publish the International ... official journal of the Taiwan Fuzzy Systems Association (TFSA). ... global visibility in the area of fuzzy research., The ... to presenting high-quality papers that deal with the theory, ... gray systems and extension theory systems ranging from hardware ...
(Date:7/23/2014)... , July 23, 2014   MedNet ... specializing in clinical study management systems, is pleased ... a proven life sciences industry executive with over ... Operating Officer (COO).  Clareece will be responsible for ... growth, operational efficiency and quality product/service delivery.  ...
(Date:7/23/2014)... Streptococcus mutans , one of the principal bacteria ... in its genetic material over time, possibly coinciding ... humanity. This is highlighted in a study ... (UAB) and the Laboratorio Nacional de Genmica para ... in Mexico who, for the first time, have ...
Breaking Biology News(10 mins):MedNet Appoints Clareece West As Chief Operating Officer 2Ancient genetic material from caries bacterium obtained for the first time 2
... (NASDAQ: MASI ) today announced that its management ... Health Care Conference at the New York Palace Hotel in New York ... A live audiocast of the presentation will be available on ... the audiocast will be available following the live presentation. ...
... have suggested that climate change is causing additional stress to ... consider a significant reduction, or in some places elimination of ... growing degradation of grazing lands could be mitigated if large ... lands became free of use by livestock and "feral ungulates" ...
... CINCINNATIA University of Cincinnati (UC) Cancer Institute lung cancer ... be isolatedand then grownin a preclinical model, offering a ... target stem cells. John C. Morris, MD, ... 13, 2012, issue of PLOS One , a ...
Cached Biology News:Masimo to Present at 24th Annual Piper Jaffray Health Care Conference 2Masimo to Present at 24th Annual Piper Jaffray Health Care Conference 3Climate change increases stress, need for restoration on grazed public lands 2Climate change increases stress, need for restoration on grazed public lands 3Stem cell finding could advance immunotherapy for lung cancer 2